<DOC>
	<DOC>NCT02432261</DOC>
	<brief_summary>This is a prospective, randomized, double-blinded, two-center trial to evaluate the gonadotropin suppressive activity of transdermal treatment with a combined NES/T gel, or T gel alone, for 28 days.</brief_summary>
	<brief_title>Evaluate the Pharmacokinetics and Gonadotropin Suppression of Nestorone®-Testosterone (NES/T) Combination Gel in Men</brief_title>
	<detailed_description>A total of 45 subjects will be enrolled and randomized in a 2:1 ratio to one of two treatment groups. A description of each group is as follows: - Group 1 (30 subjects): 5.0 mL of the 1.62% combined gel (containing 8.3 mg NES + 62.5 mg T) applied each day on the arms and shoulders - Group 2 (15 subjects): 4.4 mL of the 1.62% AndrogelTM (containing 62.7 mg T) applied each day to the arms and shoulders The total duration of treatment will be 28 days followed by a 72 hour sampling period to assess half-life and a recovery period of at least 28 days, at which point the subjects will return to the clinic for an end of study visit.</detailed_description>
	<mesh_term>ST 1435</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1. Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening; 2. 18 to 50 years of age; 3. BMI &lt; 33 calculated as weight in Kg/(height in cm)2; 4. No history of hormonal therapy use in the last six months prior to the first screening visit; 5. Subject will agree to use a recognized effective method of contraception with his partner (i.e. at a minimum, condom for the male partner and an effective contraception for the female partner) during the course of the study treatment and recovery phase; 6. In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form; 7. Does not meet any of the exclusion criteria. 8. Sperm concentration ≥ 15 million sperm per milliliter ejaculate. 1. Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit; 2. Men not living in the catchment's area of the clinic or within a reasonable distance from the site; 3. Clinically significant abnormal physical findings at screening; 4. Elevated PSA (levels ≥ 4 ng/mL), according to local laboratory normal values; 5. Abnormal serum chemistry values, according to local laboratory normal values that indicate liver or kidney dysfunction or that may be considered clinically significant; 6. Use of androgens or body building substances within 6 months before first screening visit; 7. Diastolic blood pressure (DBP) &gt; 80 and/or Systolic (SBP) &gt; 130 mm Hg; 8. EKG abnormal and clinically significant and QTC level longer than 450msec; 9. History of hypertension, including hypertension controlled with treatment; 10. Known history of primary testicular disease or disorders of the hypothalamicpituitary axis; 11. Known hypersensitivity to progestins or androgen; 12. Family or personal history of venous thromboembolism; 13. Benign or malignant liver tumors; active liver disease; 14. Known history of reproductive dysfunction including vasectomy or infertility; 15. Known history of cardiovascular, renal, hepatic or prostatic disease; 16. A serious systemic disease such as diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body weight or BMI limitation as above); 17. Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance; 18. Known dermatitis or severe skin disorder; 19. Moderate or severe depression as determined by PHQ9 score &gt;15; 20. Partner is known to be pregnant; 21. Known or suspected breast or prostate cancer; 22. Allergic to any ingredient in testosterone/nestorone gel, including alcohol; 23. Known history of untreated sleep apnea; 24. International Prostate Symptom Score (IPSS) greater than or equal to 15.</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>spermatogenesis</keyword>
	<keyword>androgen</keyword>
	<keyword>male contraception</keyword>
</DOC>